Patents Examined by Cherie M Stanfield
-
Patent number: 9688752Abstract: The present invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods for producing such low AR compositions using displacement chromatography. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.Type: GrantFiled: March 2, 2015Date of Patent: June 27, 2017Assignee: AbbVie Inc.Inventors: Chen Wang, Germano Coppola, Chris Chumsae
-
Patent number: 9683033Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of acidic species expressed by host cells, as well as to compositions and processes for controlling the amount of acidic species present in purified preparations.Type: GrantFiled: January 28, 2016Date of Patent: June 20, 2017Assignee: ABBVIE, INC.Inventors: Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Christopher Chumsae
-
Patent number: 9683026Abstract: Compositions and methods relating to WSX-1 and p28 (IL-30) are provided. In particular, methods of treating inflammatory conditions in mammalian subjects using various WSX-1, p28, EBI3, and gp130 polypeptides and complexes or moieties that bind to or modulate activity of such complexes are described. Isolated or recombinant complexes including soluble WSX-1 or gp130 polypeptides, isolated or recombinant WSX-1 fusion proteins, and isolated or recombinant p28 fusion proteins are also described.Type: GrantFiled: July 18, 2007Date of Patent: June 20, 2017Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSLYVANIAInventors: Christopher A. Hunter, Jason Scott Stumhofer
-
Patent number: 9684000Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.Type: GrantFiled: September 9, 2013Date of Patent: June 20, 2017Assignee: GENENTECH, INC.Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
-
Patent number: 9675702Abstract: Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.Type: GrantFiled: July 21, 2015Date of Patent: June 13, 2017Assignee: JDS Therapeutics, LLCInventor: James R. Komorowski
-
Patent number: 9671411Abstract: An improved monocyte activation test is described that is better able to detect non-endotoxin pyrogens in medical products, in which a sample is incubated with a monocyte-containing reagent in an assay system comprising at least one surface comprising polypropylene. The invention also concerns assay systems for use in these tests that include at least one microtiter well having at least one interior surface comprising polypropylene and having a shape such that monocyte-containing reagent is concentrated in the well to provide greater cell to cell contact. The invention also relates to a diagnostic kit that can be used to test for the presence of non-endotoxin pyrogens in a sample.Type: GrantFiled: April 6, 2015Date of Patent: June 6, 2017Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA, THE SECRETARY OF STATE FOR HEALTHInventors: Stephen Poole, Mehul Patel
-
Patent number: 9616155Abstract: Fixation devices for tissue repair, for example sutures, surgical arrows, staples, darts, bolts, screws, buttons, anchors, nails, rivets, or barbed devices comprise at least one of angiogenic material; angiogenic precursor material which is capable of breaking down in vivo to form angiogenic material; or tissue-engineered material, which tissue-engineered material is capable of producing angiogenic material. In a preferred form, the material is incorporated into a polymer matrix having predetermined hydrophobicity to allow controlled release of angiogenic materials such as butyric or hydroxybutyric acid or salts thereof. Polymer matrix compositions comprising angiogenic materials and methods for tissue repair are also provided.Type: GrantFiled: June 15, 2009Date of Patent: April 11, 2017Assignee: Smith & Nephew, Inc.Inventors: Nicholas J. Cotton, Emma J. Wright, Steven W. Astorino, Saad Ali
-
Patent number: 9597372Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.Type: GrantFiled: November 25, 2014Date of Patent: March 21, 2017Assignees: The Regents of the University of California, The United States of America as represented by the Department of Veterans AffairsInventors: Leonard H. Rome, Valerie A. Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar
-
Patent number: 9597404Abstract: Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.Type: GrantFiled: July 21, 2015Date of Patent: March 21, 2017Assignee: JDS Therapeutics, LLCInventor: James R. Komorowski
-
Patent number: 9585938Abstract: Observations regarding the role of MUC1 in promoting the nuclear accumulation of EGFR led us to propose the development of peptides to block nuclear accumulation of EGFR as a means to block breast cancer progression. One exemplary peptide, the ENLS1 peptide, promotes cell death in breast cancer cell lines. Studies in the MMTV-pyMT mouse model of breast cancer demonstrate significant anti-tumor activity.Type: GrantFiled: October 12, 2011Date of Patent: March 7, 2017Assignee: ARIZONA CANCER THERAPEUTICS, LLCInventors: Joyce A. Schroeder, Benjamin G. Bitler, Aarthi Goverdhan
-
Patent number: 9580460Abstract: The invention is based on the discovery that the presence of a discordant helix in a protein or peptide is predictive of that protein or peptide's ability to form amyloid. The invention includes methods for detecting discordant helices and methods of screening for compounds that stabilize the ?-helix of a discordant helix-containing polypeptide. Compounds discovered using these methods are useful for treating or preventing disorders in which amyloid is produced. Such disorders include Alzheimer's disease and prion-associated disorders.Type: GrantFiled: November 8, 2013Date of Patent: February 28, 2017Assignee: AlphaBeta ABInventor: Jan Johansson
-
Patent number: 9573717Abstract: Compositions of and methods for formulating and delivering biologically active agent formulations having enhanced physical stability, and wherein deterioration from the presence of oxygen and/or water is minimized and/or controlled, to yield a stable formulation. The compositions of and methods for formulating and delivering biologically active agents of the present invention further facilitate their incorporation into a biocompatible coating which can be employed to coat a stratum-corneum piercing microprojection, or a plurality of stratum-corneum piercing microprojections of a delivery device, for delivery of the biocompatible coating through the skin of a subject, thus providing an effective means of delivering the biologically active agents.Type: GrantFiled: January 21, 2014Date of Patent: February 21, 2017Assignee: ALZA CORPORATIONInventors: Mahmoud Ameri, Michel J. N. Cormier, Scott Sellers, Yuh-Fun Maa
-
Patent number: 9573986Abstract: The present invention provides a peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and/or a non-amino acid compound, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 22, 2010Date of Patent: February 21, 2017Assignee: KENJI KANGAWAInventors: Kenji Kangawa, Masayasu Kojima, Hiroshi Hosoda, Hisayuki Matsuo, Yoshiharu Minamitake
-
Patent number: 9566331Abstract: A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-?, and IFN-?, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.Type: GrantFiled: February 20, 2013Date of Patent: February 14, 2017Assignee: IRX Therapeutics, Inc.Inventors: John W. Hadden, Kathy L. Signorelli, James E. Egan, Paul H. Naylor
-
Patent number: 9550837Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.Type: GrantFiled: June 12, 2015Date of Patent: January 24, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald
-
Patent number: 9539321Abstract: The invention provides an immtmostimulatory peptide containing the amino acid sequence SAFFLFCSE and uses thereof. The invention also provides an immunostimulatory peptide containing the amino acid sequence DPNAPKRPPSAFFLX1X2X3X4 or derivatives thereof. In one embodiment, when X1 is alanine (A), glycine (G), or valine (V) then X2 is C, X3 is S and X4 is E; wherein when X2 is alanine (A), glycine (G), or valine (V) then X1 is F, X3 is S and X4 is E; wherein when X3 is alanine (A), glycine (G), or valine (V) then X1 is F, X2 is C and X4 is E; or wherein when X4 is alanine (A), glycine (G), or valine (V) then X1 is F, X2 is C and X3 is S.Type: GrantFiled: March 9, 2015Date of Patent: January 10, 2017Assignee: The Regents of the University of CaliforniaInventors: Davorka Messmer, Rebecca Saenz
-
Patent number: 9539284Abstract: A method of selecting or determining a candidate compound suitable for use as a phosphate binder is disclosed. The candidate compound includes ferric compounds, ferric compound complexes, and their derivatives, salts, analogs, and metabolites. The effectiveness of the candidate compound as a phosphate binder is evaluated by a method, comprising measuring and correlating reduction of phosphate concentration in solution and reduction of phosphate absorption in cells.Type: GrantFiled: January 12, 2015Date of Patent: January 10, 2017Assignee: Panion & BF Biotech Inc.Inventor: Keith Chan
-
Patent number: 9539320Abstract: A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-?, and IFN-?, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.Type: GrantFiled: May 17, 2010Date of Patent: January 10, 2017Assignee: IRX Therapeutics, Inc.Inventors: John W. Hadden, Kathy Signorelli, James Egan, Paul Naylor
-
Patent number: 9535057Abstract: This invention relates to a method of screening agents for cardiotoxicity based on the observations of the alteration of heart rate and heart rhythm, using teleost embryos and larvae. This invention also relates to a method for identification of gene(s) related to cardiac functions in teleost.Type: GrantFiled: January 8, 2007Date of Patent: January 3, 2017Assignee: CITY UNIVERSITY OF HONG KONGInventors: Shuk Han Cheng, Po Kwok Chan
-
Patent number: 9534013Abstract: The subject invention provides a method for purifying a target protein from a mixture comprising the target protein and contaminating protein, comprising the steps of exposing the mixture to an effective amount of a cationic surfactant such that the contaminating protein is preferentially precipitated and recovering the target protein. Proteins purified according to the method of the invention are also provided.Type: GrantFiled: April 12, 2006Date of Patent: January 3, 2017Assignee: Horizon Pharma Rheumatology LLCInventors: Meir Fischer, Eliyahu Harosh